138 related articles for article (PubMed ID: 31955703)
1. Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center.
Laird CM; Glode AE; Schwarz K; Lam ET; O'Bryant CL
J Oncol Pharm Pract; 2020 Sep; 26(6):1369-1373. PubMed ID: 31955703
[TBL] [Abstract][Full Text] [Related]
2. Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study.
Boccia R; Geller RB; Clendeninn N; Ottoboni T
Future Oncol; 2019 Jan; 15(3):297-303. PubMed ID: 30301373
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
[TBL] [Abstract][Full Text] [Related]
4. Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
Chau E; Lundberg J; Phillips G; Berger M; Wesolowski R
J Oncol Pharm Pract; 2019 Jul; 25(5):1053-1057. PubMed ID: 29651918
[TBL] [Abstract][Full Text] [Related]
5. Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis.
Burns D; Kula J; Marshall S; Ashworth E; Ornelas M
Adv Ther; 2020 Jul; 37(7):3265-3277. PubMed ID: 32447650
[TBL] [Abstract][Full Text] [Related]
6. Systemic hypersensitivity to fosaprepitant - A report of two cases.
Baxley A; Lee Z; Medina P
J Oncol Pharm Pract; 2018 Jan; 24(1):76-78. PubMed ID: 27872331
[TBL] [Abstract][Full Text] [Related]
7. An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy.
Hegerova LT; Leal AD; Grendahl DC; Seisler DK; Sorgatz KM; Anderson KJ; Hilger CR; Loprinzi CL
Support Care Cancer; 2015 Jan; 23(1):55-9. PubMed ID: 24964876
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of intravenous aprepitant and fosaprepitant in children with cancer: A retrospective, single-center review.
Kanukollu S; Spatz K; Lavery JA; Bender JG; Mauguen A; Mathew S
Pediatr Blood Cancer; 2024 Apr; 71(4):e30882. PubMed ID: 38267822
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of aprepitant and fosaprepitant in pediatric patients.
Saito Y; Kumamoto T; Arima T; Shirakawa N; Ishimaru S; Sonoda T; Nakajima M; Sugiyama M; Arakawa A; Hashimoto H; Makino Y; Ogawa C; Yamaguchi M
Pediatr Int; 2019 Mar; 61(3):235-239. PubMed ID: 30615239
[TBL] [Abstract][Full Text] [Related]
10. Benefits and Risks of Fosaprepitant in Patients Receiving Emetogenic Regimens.
Pritchett W; Kinsley K
Clin J Oncol Nurs; 2016 Oct; 20(5):555-6. PubMed ID: 27668376
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients.
Mora J; Valero M; DiCristina C; Jin M; Chain A; Bickham K
Pediatr Blood Cancer; 2019 Jun; 66(6):e27690. PubMed ID: 30900392
[TBL] [Abstract][Full Text] [Related]
12. Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.
Rapoport BL; Jordan K; Weinstein C
Future Oncol; 2018 Jan; 14(1):77-92. PubMed ID: 29130344
[TBL] [Abstract][Full Text] [Related]
13. Infusion Site Reactions: Classification in the Setting of Fosaprepitant Administration With Chemotherapy.
Segna AN; Baron RH; Cohen B
Clin J Oncol Nurs; 2020 Dec; 24(6):E79-E84. PubMed ID: 33216065
[TBL] [Abstract][Full Text] [Related]
14. Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects.
Ottoboni T; Lauw M; Keller MR; Cravets M; Manhard K; Clendeninn N; Quart B
Future Oncol; 2018 Nov; 14(27):2849-2859. PubMed ID: 29873529
[TBL] [Abstract][Full Text] [Related]
15. Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy.
Leal AD; Kadakia KC; Looker S; Hilger C; Sorgatz K; Anderson K; Jacobson A; Grendahl D; Seisler D; Hobday T; Loprinzi CL
Support Care Cancer; 2014 May; 22(5):1313-7. PubMed ID: 24402411
[TBL] [Abstract][Full Text] [Related]
16. Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: A double-blind, placebo-controlled, phase III randomized trial.
Radhakrishnan V; Joshi A; Ramamoorthy J; Rajaraman S; Ganesan P; Ganesan TS; Dhanushkodi M; Sagar TG
Pediatr Blood Cancer; 2019 Mar; 66(3):e27551. PubMed ID: 30426714
[TBL] [Abstract][Full Text] [Related]
17. Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
Lundberg JD; Crawford BS; Phillips G; Berger MJ; Wesolowski R
Support Care Cancer; 2014 Jun; 22(6):1461-6. PubMed ID: 24402412
[TBL] [Abstract][Full Text] [Related]
18. Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy.
Ando Y; Hayashi T; Ito K; Suzuki E; Mine N; Miyamoto A; Oya M; Matsuda H; Isaji A; Nakanishi T; Imaizumi K; Shibata T; Okada T; Sakurai K; Naito K; Uyama I; Kawada K; Takahashi H; Yamada S
Support Care Cancer; 2016 Feb; 24(2):871-878. PubMed ID: 26206077
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Use of Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients.
Timaeus S; Elder J; Franco K
J Pediatr Hematol Oncol; 2018 Oct; 40(7):527-531. PubMed ID: 29794645
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Pong A; Noga SJ; Rapoport BL
Support Care Cancer; 2018 Nov; 26(11):3773-3780. PubMed ID: 29808377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
